Palatin Technologies, Inc.
In the quarter to June 2026, revenue fell 14.1%, EPS fell 276.3% and free cash flow grew 34.2%, each against the same quarter a year earlier.
Follow PTN
Palatin Technologies, Inc. (PTN) EV/Sales
As of 16 October 2026, Palatin Technologies, Inc. (PTN) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −580× (December 2020) to 588× (November 2021); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.8× | (38.85%) |
| FY2024 | 2.9× | 15.69% |
| FY2023 | 2.5× | (90.29%) |
| FY2022 | 25.5× | — |
| FY2021 | −453× | — |
| FY2020 | 0.6× | (68.75%) |
| FY2019 | 2.0× | (12.59%) |
| FY2018 | 2.3× | 198.74% |
| FY2017 | 0.8× | (88.79%) |
| FY2015 | 7.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.8× | (60.04%) |
| Mar 2026 | 4.4× | 101.62% |
| Dec 2025 | 2.2× | 343.40% |
| Sep 2025 | 0.5× | (82.88%) |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ASBP Aspire-Lakewood Holdings, Inc. compare | −2.7× |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| PTN Palatin Technologies, Inc. | 0.7× |
| ENSC Ensysce Biosciences, Inc. compare | 1.5× |
| PLUR Pluri Inc. compare | 29.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)